CDC logo, Safer Healthier People  CDC HomeCDC SearchCDC Health Topics A-Z
NIOSH - National Institute for Occupational Safety and Health

Search NIOSH  |  NIOSH Home  |  NIOSH Topics  |  Site Index  |  Databases and Information Resources  |  NIOSH Products  |  Contact Us






2 - Oxetanone

RTECS #: RQ7350000

CAS #: 57-57-8


UPDATE: May 2009 MW: 72.07 MF: C3H4O2


NOTE:

TABLE OF CONTENTS:
  1. SYNONYMS:
  2. MUTATION DATA:
  3. TUMORIGENIC DATA:
  4. ACUTE TOXICITY DATA:
  5. REVIEWS:
  6. STANDARDS AND REGULATIONS:
  7. NIOSH DOCUMENTATION AND SURVEILLANCE:
  8. STATUS IN FEDERAL AGENCIES:
  9. REFERENCES:

SYNONYMS:

  1. 1,3 - Propiolactone
  2. 3 - Hydroxypropionic acid lactone
  3. 3 - Propanolide
  4. 3 - Propiolactone
  5. BPL
  6. Betaprone
  7. Hydracrylic acid beta - lactone
  8. Propanolide
  1. Propiolactone
  2. Propionic acid, 3 - hydroxy - , beta - lactone
  3. beta - PL
  4. beta - Propiolactone
  5. beta - Propiolactone (ACGIH:OSHA)
  6. beta - Propiolakton (Czech)
  7. beta - Propionolactone
  8. beta - Proprolactone


SKIN AND EYE IRRITATION DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
N/R
N/R N/R N/R


MUTATION DATA AND REFERENCES:

SYSTEM TEST ROUTE/
ORGANISM/
TISSUE
DOSE REFERENCE
cytogenetic analysis hamster fibroblast 30 mg/L/24 hour MUREAV 48,337,1977
cytogenetic analysis hamster lung 18 mg/L GMCRDC 27,95,1981
cytogenetic analysis hamster ovary 200 µg/L ENMUDM 7,1,1985
cytogenetic analysis human fibroblast 13 mg/L CNREA8 46,4720,1986
cytogenetic analysis human HeLa cell 100 nmol/L TXCYAC 9,21,1978
cytogenetic analysis rat leukocyte 250 µmol/L/5 hour LBANAX 3,157,1969
DNA adduct Escherichia coli 10 µmol/L MUREAV 89,95,1981
DNA adduct mammal (species unspecified) lymphocyte 1,600 µmol/L/20 hour CBINA8 18,327,1977
DNA adduct mouse liver 1,600 µmol/L/20 hour CBINA8 18,327,1977
DNA damage Bacillus subtilis 110 nmol/L CNREA8 41,4368,1981
DNA damage hamster lung 100 µmol/L/1 hour BBRCA9 72,732,1976
DNA damage hamster embryo 2,500 µg/L CBINA8 13,105,1976
DNA damage human lymphocyte 1 mmol/L JACTDZ 1(3),125,1982
DNA damage skin
mouse
8 nmol/kg ANYAA9 163,751,1969
DNA damage mouse Ascites tumor 12 mmol/L CNREA8 36,3025,1976
DNA damage intraperitoneal
mouse
100 mg/kg MUREAV 493,39,2001
DNA damage oral
mouse
150 mg/kg MUREAV 493,39,2001
DNA damage other microorganisms 10 mmol/L JGAMA9 19,339,1973
DNA damage other microorganisms 1,000 ppm CBINA8 10,41,1975
DNA damage other microorganisms 2 pph CBINA8 10,41,1975
DNA damage other microorganisms 1,600 µmol/L PNASA6 73,2629,1976
DNA damage rat liver 30 µmol/L MUREAV 368,59,1996
DNA damage oral
rat
100 mg/kg CNREA8 38,1589,1978
DNA damage rat liver 100 µmol/L/3 hour MUREAV 629,49,2007
DNA inhibition human HeLa cell 500 µmol/L MUREAV 92,427,1982
DNA inhibition skin
mouse
8,600 µmol/kg CNREA8 33,769,1973
DNA inhibition other microorganisms 5 mmol/L JGAMA9 19,339,1973
DNA repair Escherichia coli 10 µg/disc JJIND8 62,873,1979
unscheduled DNA synthesis Escherichia coli 15 mmol/L ZKKOBW 92,177,1978
unscheduled DNA synthesis human fibroblast 160 µg/L TXCYAC 21,151,1981
unscheduled DNA synthesis skin
mouse
8,600 µmol/kg CNREA8 33,769,1973
unscheduled DNA synthesis mouse other cell types 500 µmol/L JIDEAE 62,480,1974
unscheduled DNA synthesis mouse fibroblast 500 µmol/L JIDEAE 62,480,1974
host-mediated assay mouse
Salmonella typhimurium
405 mg/kg JJIND8 62,911,1979
mutation in microorganisms Escherichia coli 1 µL/plate (+/-enzymatic activation step) PMRSDJ 1,387,1981
mutation in microorganisms mouse lymphocyte 15 mg/L/4 hour (+enzymatic activation step) MUREAV 59,61,1979
mutation in microorganisms Neurospora crassa 2 µg/plate (-enzymatic activation step) MUREAV 53,297,1978
mutation in microorganisms other microorganisms 2 gm/L (-enzymatic activation step) MOPMA3 6,667,1970
mutation in microorganisms other microorganisms 450 µmol/L (-enzymatic activation step) CNREA8 42,3480,1982
mutation in microorganisms other microorganisms 667 ppm/1 hour (-enzymatic activation step) MUREAV 34,175,1976
mutation in microorganisms Salmonella typhimurium 1 µg/plate (+enzymatic activation step) ENMUDM 5(Suppl 1),3,1983
mutation in microorganisms Saccharomyes cerevisiae 89 mg/L (+/-enzymatic activation step) PMRSDJ 1,414,1981
mutation in microorganisms Saccharomyes cerevisiae 1 mmol/L/2 hour MUREAV 616,119,2007
mutation in microorganisms Serratia marcescens 2 gm/L (-enzymatic activation step) ATXKA8 28,93,1971
mutation in microorganisms Schizosaccharomyces pombe 100 µg/L (+/-enzymatic activation step) PMRSDJ 1,424,1981
micronucleus test intraperitoneal
mouse
54 mg/kg/24 hour- continuous MUREAV 216,321,1989
gene conversion and mitotic recombination Saccharomyes cerevisiae 1 µg/plate PMRSDJ 1,456,1981
mutation in mammalian somatic cells hamster ovary 10 mg/L MUREAV 94,449,1982
mutation in mammalian somatic cells hamster lung 2 mmol/L ENMUDM 6,426,1984
mutation in mammalian somatic cells mouse lymphocyte 2 mg/L/2 hour MUREAV 59,61,1979
morphological transform intraperitoneal
hamster
250 mg/kg ARPAAQ 95,380,1973
morphological transform hamster embryo 2,500 µg/L CBINA8 13,105,1976
morphological transform hamster kidney 80 µg/L BJCAAI 37,873,1978
morphological transform human other cell types 7,500 µg/L CNREA8 41,5096,1981
morphological transform human fibroblast 28 µmol/L PNASA6 80,7219,1983
morphological transform mouse embryo 100 µg/L PMRSDJ 5,659,1985
other mutation test systems Bacillus subtilis 50 mmol/L JOBAAY 136,854,1978
other mutation test systems mouse other cell types 57 gm/L BCPCA6 23,937,1974
other mutation test systems other microorganisms 5 mmol/L JGAMA9 19,339,1973
other mutation test systems Salmonella typhimurium 8,300 µg/L MUREAV 192,239,1987
phage inhibition capacity Escherichia coli 340 nmol/plate PNASA6 79,5971,1982
phage inhibition capacity other microorganisms 1 mg/plate ZMMPAO 231,369,1975
phage inhibition capacity Salmonella typhimurium 500 ppm CNREA8 30,830,1970
sister chromatid exchange hamster ovary 100 µmol/L NATUAS 258,121,1975
sister chromatid exchange hamster lung 100 µmol/L MUREAV 118,103,1983
sex chromosome loss and nondisjunction oral
Drosophila melanogaster
250 ppm ENMUDM 6,189,1984
sex chromosome loss and nondisjunction parenteral
Drosophila melanogaster
10 mmol/L MUREAV 66,55,1979
sex chromosome loss and nondisjunction Saccharomyes cerevisiae 25 mg/L PMRSDJ 1,468,1981
specific locus test oral
Drosophila melanogaster
200 mmol/L ENMUDM 6,153,1984
heritable translocation test parenteral
Drosophila melanogaster
25 mmol/L MUREAV 66,55,1979


REPRODUCTIVE EFFECTS DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
N/R
N/R N/R N/R


TUMORIGENIC DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
inhalation
rat
lowest published toxic concentration: 5 ppm/6 hour/30 day- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Olfaction: Tumors
JJIND8 79,285,1987
intratracheal
rat
lowest published toxic dose: 72 mg/kg/30 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Lung, Thorax, or Respiration: Bronchogenic carcinoma
BJCAAI 20,134,1966
intravenous
mouse
lowest published toxic dose: 40 mg/kg Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Skin and Appendages: Tumors

Tumorigenic: Tumors at site of application
BJCAAI 10,357,1956
oral
mouse
lowest published toxic dose: 3,080 mg/kg/77 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Tumors
JJIND8 63,1433,1979
oral
mouse
toxic dose : 320 mg/kg/8 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Tumors
CNREA8 43,4747,1983
oral
rat
lowest published toxic dose: 2,868 mg/kg/1 year- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Tumors

Liver: Tumors
BJCAAI 46,924,1982
oral
rat
toxic dose : 3,050 mg/kg/61 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Tumors
JNCIAM 37,825,1966
rectal
rat
lowest published toxic dose: 857 mg/kg/6 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Colon tumors
CNREA8 48,2740,1988
subcutaneous
mouse
lowest published toxic dose: 69 mg/kg/43 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Tumorigenic: Tumors at site of application
BJCAAI 19,392,1965
subcutaneous
mouse
toxic dose : 648 mg/kg/54 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Tumorigenic: Tumors at site of application
JJIND8 63,1433,1979
subcutaneous
mouse
toxic dose : 408 mg/kg/34 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Tumorigenic: Tumors at site of application
JNCIAM 53,695,1974
subcutaneous
mouse
toxic dose : 1,168 mg/kg/40 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Tumorigenic: Tumors at site of application
JNCIAM 37,825,1966
subcutaneous
rat
lowest published toxic dose: 22 mg/kg/25 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Tumorigenic: Tumors at site of application
BMBUAQ 20,96,1964
subcutaneous
rat
toxic dose : 50 mg/kg/25 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Tumorigenic: Tumors at site of application
BJCAAI 15,85,1961
subcutaneous
rat
toxic dose : 1,080 mg/kg/54 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Tumorigenic: Tumors at site of application
JNCIAM 39,1213,1967
skin
guinea pig
lowest published toxic dose: 56 mg/kg/141 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Liver: Tumors

Skin and Appendages: Tumors
BJCAAI 20,200,1966
skin
mouse
lowest published toxic dose: 6,200 mg/kg/15 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Skin and Appendages: Tumors
BJCAAI 9,177,1955
skin
mouse
toxic dose : 8,100 mg/kg/27 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Endocrine: Tumors

Skin and Appendages: Tumors
BJCAAI 10,357,1956
skin
mouse
toxic dose : 11 gm/kg/56 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Skin and Appendages: Tumors

Tumorigenic: Tumors at site of application
TXCYAC 6,139,1976
skin
mouse
toxic dose : 37,772 mg/kg/2 year- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Skin and Appendages: Tumors

Tumorigenic: Tumors at site of application
FCTOD7 23,1081,1985


ACUTE TOXICITY DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
inhalation
rat
lethal concentration (50 percent kill): 25 ppm/6 hour N/R 85INA8 5,497,1986
intraperitoneal
mouse
lethal dose (50 percent kill): 405 mg/kg N/R JJIND8 62,911,1979


OTHER MULTIPLE DOSE DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
N/R
N/R N/R N/R


REVIEWS:

ORGANIZATION STANDARD
REFERENCE

American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value time-weighted average 0.5 ppm DTLVS* TLV/BEI,2007
American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value Confirmed animal carcinogen DTLVS* TLV/BEI,2007
International Agency for Research on Cancer (IARC) Cancer Review Animal Sufficient Evidence IMEMDT 4,259,1974
International Agency for Research on Cancer (IARC) Cancer Review Animal Sufficient Evidence IMEMDT 71,1103,1999
International Agency for Research on Cancer (IARC) Cancer Review Human No Adequate Data IMEMDT 4,259,1974
International Agency for Research on Cancer (IARC) Cancer Review Human No Adequate Data IMEMDT 71,1103,1999
International Agency for Research on Cancer (IARC) Cancer Review Group 2B IMEMDT 71,1103,1999
TOXICOLOGY REVIEW
ENVRAL 7,243,1974
TOXICOLOGY REVIEW
22HAAD 6,409,1971
TOXICOLOGY REVIEW
MUTAEX 14,141,1999
TOXICOLOGY REVIEW
MUREAV 627,10,2007
TOXICOLOGY REVIEW
MUREAV 584,1,2005
TOXICOLOGY REVIEW
MUREAV 654,114,2008
TOXICOLOGY REVIEW
MUREAV 654,114,2008


STANDARDS AND REGULATIONS:

ORGANIZATION STANDARD
REFERENCE

Mine Safety and Health Administration (MSHA) STANDARD SUSPECTED CARCINOGEN DTLWS* 3,27,1972
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction) see Code of Federal Regulations (CFR) 29,1926.1113 CFRGBR 29,1926.55,1994
Occupational Safety and Health Administration (OSHA) cancer suspect agent CFRGBR 29,1910.1013,1987
Occupational Exposure Limit - AUSTRALIA time-weighted average 0.5 ppm (1.5 mg/m3), Carcinogen, JUL2008
Occupational Exposure Limit - BELGIUM time-weighted average 0.5 ppm (1.5 mg/m3), Carcinogen, MAR2002
Occupational Exposure Limit - DENMARK time-weighted average 0.1 ppm (1.5 mg/m3), OCT 2002
Occupational Exposure Limit - FINLAND Carcinogen, JAN1999
Occupational Exposure Limit - HUNGARY ceiling concentration 1.5 mg/m3, Carcinogen, SEP2000
Occupational Exposure Limit - KOREA time-weighted average 0.5 ppm (1.5 mg/m3), 2006
Occupational Exposure Limit - NEW ZEALAND time-weighted average 0.5 ppm (1.5 mg/m3), JAN2002
Occupational Exposure Limit - POLAND MAC(time-weighted average) 1 mg/m3, JAN1999
Occupational Exposure Limit - SWEDEN Group B Carcinogen, JUN2005
Occupational Exposure Limit - SWITZERLAND MAK- week 0.5 ppm (1.5 mg/m3), Skin, Carcinogen, DEC2006
Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value;

Confirmed animal carcinogen
Occupational Exposure Limit IN SINGAPORE, VIETNAM American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value
Confirmed animal carcinogen


NIOSH DOCUMENTATION AND SURVEILLANCE:

ORGANIZATION STANDARD or SURVEY
REFERENCE

National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO beta-PROPIOLACTONE-air Carcinogen use 29 Code of Federal Regulations (CFR) 1910.1013 NIOSH* DHHS #92-100,1992
National Occupational Hazard Survey 1974 National Occupational Hazard Survey 1974: Hazard Code: 62270;
Number of Industries 1;
Total Number of Facilities 19;
Number of Occupations 1;
Total Number of Employees Exposed 38


STATUS IN FEDERAL AGENCIES:

ORGANIZATION
REFERENCE

EPA GENETOX PROGRAM 1988, Positive: Carcinogenicity-mouse/rat; SHE-focus assay
EPA GENETOX PROGRAM 1988, Positive: Cell transform.-SA7/SHE
EPA GENETOX PROGRAM 1988, Positive: D melanogaster-reciprocal translocation
EPA GENETOX PROGRAM 1988, Positive: Host-mediated assay; L5178Y cells in vitro-TK test
EPA GENETOX PROGRAM 1988, Positive: N crassa-forward mutation; N crassa-reversion
EPA GENETOX PROGRAM 1988, Positive: E coli polA without S9; Histidine reversion-Ames test
EPA GENETOX PROGRAM 1988, Positive: D melanogaster Sex-linked lethal
EPA GENETOX PROGRAM 1988, Positive: In vitro UDS-human fibroblast
EPA GENETOX PROGRAM 1988, Positive: S cerevisiae gene conversion; S cerevisiae-homozygosis
EPA GENETOX PROGRAM 1988, Positive: S cerevisiae-reversion
EPA GENETOX PROGRAM 1988, Positive/dose response: In vitro SCE-nonhuman
EPA GENETOX PROGRAM 1988, Negative: Sperm morphology-mouse
EPA GENETOX PROGRAM 1988, Inconclusive: Mammalian micronucleus
EPA GENETOX PROGRAM 1988, Positive: CHO gene mutation
EPA TSCA Section 8(b) CHEMICAL INVENTORY
Used as an intermediate in the production of acrylic acids and esters
Used as a vapor sterilant, vapor phase disinfectant and in organic synthesis
On EPA IRIS database
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
NTP 11th Report on Carcinogens,2004:Reasonably anticipated to be a human carcinogen


REFERENCES:

CODEN
REFERENCE

22HAAD "Microbial Toxins, 1970-72," Ajil, S.J., et al., eds., New York, Academic Press, Inc., 1970-72
85INA8 "Documentation of the Threshold Limit Values and Biological Exposure Indices," 5th ed., Cincinnati, OH, American Conference of Governmental Industrial Hygienists, Inc., 1986
ANYAA9 Annals of the New York Academy of Sciences. (New York Academy of Sciences, 2 E. 63rd St., New York, NY 10021) V.1- 1877-
ARPAAQ Archives of Pathology. (Chicago, IL) V.5(3)-50(3), 1928-50; V.70-99, 1960-75. For publisher information, see APLMAS.
ATXKA8 Archiv fuer Toxikologie. (Berlin, Fed. Rep. Ger.) V.15-31, 1954-74. For publisher information, see ARTODN.
BBRCA9 Biochemical and Biophysical Research Communications. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959-
BCPCA6 Biochemical Pharmacology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1- 1958-
BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947-
BMBUAQ British Medical Bulletin. (Longman Group UK Ltd., Longman House, Burnt Mill, Harlow, Essex CM20 2JE, UK) V.1- 1943-
CBINA8 Chemico-Biological Interactions. (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1969-
CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402)
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941-
DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996
DTLWS* "Documentation of the Threshold Limit Values for Substances in Workroom Air," Supplements. For publisher information, see 85INA8.
ENMUDM Environmental Mutagenesis. (New York, NY) V.1-9, 1979-87. For publisher information, see EMMUEG.
ENVRAL Environmental Research. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1967-
FCTOD7 Food and Chemical Toxicology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.20- 1982-
GMCRDC Gann Monograph on Cancer Research. (Plenum Pub. Corp., 233 Spring St., New York, NY 10013) No. 11- 1971-
IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972-
JACTDZ Journal of the American College of Toxicology. (Mary Ann Liebert, Inc., 1651 Third Ave., New York, NY 10128) V.1-12, 1982-1993. Discontinued.
JGAMA9 Journal of General and Applied Microbiology. (Microbiology Research Foundation, c/o Japan Academic Soc. Center Bldg., 2-4-16 Yayoi, Bunkyo-ku, Tokyo, 113, Japan) V.1- 1955-
JIDEAE Journal of Investigative Dermatology. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1938-
JJIND8 JNCI, Journal of the National Cancer Institute. (Washington, DC) V.61-79, 1978-87. For publisher information, see JNCIEQ.
JNCIAM Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher information, see JJIND8.
JOBAAY Journal of Bacteriology. (American Soc. for Microbiology, 1913 I St., NW, Washington, DC 20006) V.1- 1916-
LBANAX Laboratory Animals. (Laboratory Animals Ltd., 1 Thrifts Mead, Theydon Bois, Essex CM16 7NF, UK) V.1- 1967-
MOPMA3 Molecular Pharmacology. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1965-
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-
MUTAEX Mutagenesis. (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1986-
NATUAS Nature. (Nature Subscription Dept., POB 1018, Manasguan, NJ 08736) V.1- 1869-
NIOSH* National Institute of Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda.
PMRSDJ Progress in Mutation Research. (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New York, NY 10017) V.1- 1981-
PNASA6 Proceedings of the National Academy of Sciences of the United States of America. (National Academy of Sciences, Printing & Pub. Office, 2101 Constitution Ave., Washington, DC 20418) V.1- 1915-
TXCYAC Toxicology. (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1- 1973-
ZKKOBW Zeitschrift fuer Krebsforschung und Klinische Onkologie. (Berlin, Fed. Rep. Ger.) V.76-92, 1971-78. For publisher information, see JCROD7.
ZMMPAO Zentralblatt fuer Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene, Abteilung 1: Originale, Reihe A: Medizinische Mikrobiologie und Parasitologie. (Stuttgart, Fed. Rep. Ger.) V.217-245, 1971-79.

Used as an intermediate in the production of acrylic acids and esters

Used as a vapor sterilant, vapor phase disinfectant and in organic synthesis

RTECS Compound Description:
   Agricultural Chemical
   Tumorigen
   Mutagen
   Human Data

Click Here for Additional Information about RTECS

NIOSH Home |  NIOSH Search  |  Site Index  |  Topic List |  Contact Us